{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-455506","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2026-11-10T21:18:54+00:00","discovered_at":"2026-11-10T21:20:00.255764+00:00","generated_at":"2026-11-10T21:20:14.630045+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BBOT Q3 net loss $34.2M; BBO-8520 combo ORR 75% at 500mg in G12C-experienced NSCLC","bullets":["Cash, cash equivalents and marketable securities totaled $315.3M at Sept 30, 2026, expected to fund operations into 2029.","Q3 net loss $34.2M vs $44.8M a year ago; R&D $29.6M (vs $35.1M) and G&A $7.9M (vs $14.1M, which included a $7.8M BridgeBio Pharma stock charge).","BBO-8520 plus pembrolizumab in 2L+ KRAS G12C inhibitor-experienced NSCLC: 75% ORR at 500mg QD, 53% across dose levels (N=17); AEs mainly GI, favorable liver profile.","BBO-8520 monotherapy in G12C inhibitor-naive NSCLC: 63% ORR (26/41), 100% DCR (41/41); 21 of 28 eligible patients remained on treatment beyond six months.","BBO-11818 plus BBO-10203 and cetuximab combination dosing started in KRAS-mutant CRC and PDAC; monotherapy data updates for both expected in Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-455506","json":"https://secwatch.observer/filing/0001193125-26-455506.json","markdown":"https://secwatch.observer/filing/0001193125-26-455506.md","text":"https://secwatch.observer/filing/0001193125-26-455506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526455506/0001193125-26-455506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526455506/bbot-20261110.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T21:20:14.630045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}